약물-기기 조합 제품 시장 규모 : 제품별, 용도별, 최종 용도별, 세계 예측, 2024-2032년

Drug Device Combination Products Market size is projected to record 7.8% CAGR from 2024 to 2032, driven by technological advancements and increasing R&D efforts. Of late, manufacturers are integrating cutting-edge technologies into drug device combination products to enhance their effectiveness and user convenience. Ongoing research is helping in developing more precise and reliable devices to improve drug delivery and patient outcomes.

Consequently, investments in technology and innovation are driving developments for ensuring that these products become more sophisticated and effective in treating a range of conditions. For instance, in December 2022, Terumo Corporation in collaboration with Kyowa Kirin introduced a drug-device combination "G-Lasta Subcutaneous Injection 3.6 mg BodyPod". This product combines an automated injector with pegfilgrastim to reduce febrile neutropenia in chemotherapy patients.

The drug device combination products market is segregated into product, application, end-use, and region.

In terms of product, the inhalers segment is expected to record significant CAGR from 2024 to 2032 due to the high integration of advanced technologies with medication delivery systems to improve treatment outcomes. Manufacturers are developing new inhalers that combine precision devices with medications to manage respiratory conditions more effectively. Moreover, the increasing advancements for incorporating features like smart technology to track usage and ensure proper medication adherence will drive the segment growth.

By application, the drug device combination products industry from the cardiovascular disorders segment is projected to rise through 2032, driven by increasing demand to improve patient outcomes. These products are providing innovative solutions by combining drugs and devices to address various cardiovascular conditions. Additionally, medical professionals are utilizing these advanced combinations to enhance treatment efficacy and patient compliance. Ongoing research is also shaping the way cardiovascular disorders are treated for promising more tailored and effective therapies for individuals.

Regionally, the Asia Pacific drug device combination products market size is projected to exhibit robust growth between 2024 and 2032, fueled by the increasing aging population and surging prevalence of chronic diseases. Researchers in APAC are developing advanced combination products to address the growing healthcare needs of older adults and those with chronic conditions The continuous advancements for enhancing combination products with improvements in drug delivery systems and integration with digital health technologies will boost the regional industry development.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for minimally invasive drug delivery devices
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Increasing prevalence of chronic diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with drug device combination products
    • 3.2.2.2 Technical challenges in drug delivery
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Drug-eluting stents
  • 5.2.1 Coronary drug-elating stents
  • 5.2.2 Peripheral drug-eluting stents
• 5.3 Infusion pumps
  • 5.3.1 Implantable infusion pumps
  • 5.3.2 Insulin infusion pumps
  • 5.3.3 Patient-controlled analgesia pumps
  • 5.3.4 Ambulatory infusion pumps
  • 5.3.5 Volumetric infusion pumps
  • 5.3.6 Disposable infusion pumps
• 5.4 Photodynamic therapy
• 5.5 Wound care combination product
• 5.6 Prefilled syringes
  • 5.6.1 Single-chamber prefilled syringes
  • 5.6.2 Dual-chamber prefilled syringes
  • 5.6.3 Customized prefilled syringes
• 5.7 Drug-eluting balloons
  • 5.7.1 Coronary drug-eluting balloons
  • 5.7.2 Peripheral drug-eluting balloons
• 5.8 Nebulizers
• 5.9 Inhalers
  • 5.9.1 Drug powdered inhalers (DPIs)
  • 5.9.2 Metered dose inhalers (MDIs)
  • 5.9.3 Soft mist inhalers (SMIs)
• 5.10 Transdermal delivery systems
  • 5.10.1 Active transdermal systems
  • 5.10.2 Passive transdermal systems
• 5.11 Orthopedic combination products
  • 5.11.1 Bone graft implants
  • 5.11.2 Antibiotic loaded bone cement
• 5.12 Antimicrobial catheters
  • 5.12.1 Urological catheters
  • 5.12.2 Cardiovascular catheters
  • 5.12.3 Other catheters
• 5.13 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cardiovascular disorders
• 6.3 Diabetes
• 6.4 Respiratory problems
• 6.5 Cancer treatment
• 6.6 Antimicrobial application
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory surgical centers
• 7.4 Home care settings
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AbbVie, Inc.
• 9.3 Alcon, Inc.
• 9.4 Bausch Health Companies Inc
• 9.5 Baxter International Inc.
• 9.6 Bayer AG
• 9.7 Becton, Dickinson and Company
• 9.8 Boston Scientific Corporation
• 9.9 GlaxoSmithKline plc
• 9.10 Johnson & Johnson
• 9.11 Kaleo, Inc.
• 9.12 Medtronic plc
• 9.13 Novartis AG
• 9.14 SINOMED
• 9.15 Smith & Nephew plc
• 9.16 Teleflex Incorporated
• 9.17 Teva Pharmaceutical Industries Ltd.